It is becoming increasingly clear that some of the most complex scientific challenges only can be achieved through interdisciplinary efforts. With the Exploratory Interdisciplinary Synergy Programme, the Novo Nordisk Foundation sought to strengthen the synergy between researchers, across disciplines, organizations and national borders. With this in mind, we assembled a new multidisciplinary consortium for this innovative project Image and Destroy: New Radionuclides for Cancer Theranostics (ID-Cancer). The team consists of Prof. Christine McKenzie (The Department of Physics, Chemistry and Pharmacy Southern Denmark University, DE), Assoc. Prof. Helge Thisgaard (Department of Nuclear Medicine, Odense University Hospital, DE) and Prof. Andrew Kellett (Dublin City University). Together we combine expertise in synthetic organic and molecular inorganic chemistry, nucleic acid chemistry, and DNA damage and repair, nuclear physics, radionuclide production, cell and small animal radioisotope uptake, clinical PET/SPECT, nuclear medicine and oncology. We aim to develop methods for enabling implementation of 119-antimony (119Sb) and 58m-cobalt (58mCo) Auger Electron Emitters (AEEs) to target and destroy of the most aggressive and deadly type of brain cancer, glioblastoma multiforme (GBM).